Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). Cellectis’ mission is to develop a new generation of cancer therapies based on engineered T-cells. Using its life-science-focused, pioneering genome-engineering technologies, the company aims to create innovative products in multiple fields and with various target markets.